Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

FDA Issues IND Number For Regen BioPharma ‘s dCellVax Therapeutic Application, A Proposed Treatment For Breast Cancer

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – November 04, 2014) – Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell…

Halozyme Therapeutics, Inc. To Host Third Quarter 2014 Financial Results Conference Call

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 3, 2014 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr…

Catheter Connections Fails Second Disinfection Test On Important Fungus, Announces Ivera Medical Corporation

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, CA–(Marketwired – November 04, 2014) – Ivera Medical announced that an independent lab has found that the dark blue IV-Pole Strips and DualCap products for male luer connectors made by Catheter Connections failed in a second test to disinfect all critical surfaces of male luer connectors when used as directed on Candida albicans. Previously, results were published…

Volcano Corporation Presentation At Conference To Be Webcast

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 4, 2014 /PRNewswire/ — Volcano Corporation (Nasdaq: VOLC), a leading company focused on improving patient and economic outcomes on a global basis by developing and delivering innovative minimally invasive coronary and peripheral visualization, physiology diagnostics and therapies, said today it…

Ignyta To Chair Workshop On Molecularly Targeted Cancer Therapies

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO–(BUSINESS WIRE)–Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced that its Chief Medical Officer, Adrian Senderowicz, M.D., has been selected to serve as Workshop Planning Committee Chair for the workshop entitled Policy Issues in the Development and Adoption of Molecularly Targeted Therapies for Cancer. The event will be hosted by the Institute of…

Abide Therapeutics Announces A Collaborative Agreement With The University of Oxford

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 4, 2014 /PRNewswire/ –Abide Therapeutics announced today that the Company has entered into a collaborative agreement with the University of Oxford and the Oxford University<…

Mo Bio Laboratories, Inc. Launches the PowerMag?? Blood DNA/RNA Isolation Kit

November 4, 2014 – 5:00 am | Edit Post

CARLSBAD, Calif., Nov. 4, 2014 /PRNewswire/ –MO BIO Laboratories, Inc., the leader in soil, stool and microbial nucleic acid purification, announces the launch of the PowerMag Blood DNA/RNA Isolation Kit. The kit is designed for automated, hands-free purification of nucleic acids from blood…

Neurocrine Biosciences, Inc. Reports Third Quarter 2014 Results

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 3, 2014 /PRNewswire/ — Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2014. For the third quarter of 2014, the Company reported a net loss of $15.9 million, or

Neurocrine Biosciences, Inc. To Present At The Biotechnology Conference

November 4, 2014 – 5:00 am | Edit Post

SAN DIEGO, Nov. 3, 2014 /PRNewswire/ –Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences, will be presenting at the Nomura Biotechnology Conference in Boston. The live presentation…

Regulus Therapeutics, Inc. Announces Closing of Public Offering Of $103.5M Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares

November 4, 2014 – 5:00 am | Edit Post

LA JOLLA, Calif., Nov. 3, 2014 /PRNewswire/ –Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the closing of its previously announced underwritten public offering of